GLP-1 Drug Decision Quiz

Four questions. Output: the FDA-approved GLP-1 medication (or two) that best matches your profile, with the underlying trial evidence cited at every branch — STEP, SURMOUNT, SELECT, FLOW, STEP-HFpEF, SURMOUNT-OSA, or STEP-TEENS — plus a link to the relevant GLP Watchdog provider ranking.

This decision support is part of GLP Watchdog' living editorial database — 270+ research articles and 570+ clinically-reviewed GLP-1 telehealth providers, sourced only from primary FDA labels and peer-reviewed PubMed literature.

Not medical advice. Decision support for patients is what this offers, built on outcomes-trial evidence and FDA-approved indications. Which medication you actually take is settled with your prescribing clinician, against your full medical history.

1234

Step 1 of 4 — Which BMI range are you in right now?

Not sure of your BMI? Run our BMI calculator first. FDA approval for chronic weight management reaches Foundayo, Saxenda, Zepbound and Wegovy at BMI ≥30 — or at ≥27 where at least one weight-related comorbidity comes with it.

Need to calculate? Use the BMI calculator →

How the recommendation logic works

The decision tree is rule-based, not AI-inferred. Every branch traces to either an FDA-approved indication on a specific drug label (Section 1: Indication and Usage) or an outcomes-trial finding from the published clinical literature.

BMI eligibility — one threshold appears on the Foundayo, Saxenda, Zepbound and Wegovy labels alike: BMI ≥30, or ≥27 carrying at least one weight-related comorbidity.
Type 2 diabetes path — T2D approval covers Rybelsus, Ozempic and Mounjaro. On HbA1c reduction the SURPASS-2 head-to-head puts tirzepatide ahead of semaglutide.
Established CV disease — SELECT (Lincoff et al, NEJM 2023, PMID 37952131) showed semaglutide 2.4 mg reduced major adverse cardiovascular events 20% (HR 0.80, 95% CI 0.72-0.90) in 17,604 non-diabetic adults with overweight/obesity and CV disease. Wegovy is preferred for this profile.
HFpEF — semaglutide has STEP-HFpEF behind it on exercise capacity and on symptoms.
T2D + CKD — FLOW trial (NEJM 2024) showed semaglutide 1 mg reduced the composite kidney outcome 24% (HR 0.76, 95% CI 0.66-0.87) in T2D + CKD. Ozempic is preferred for this profile.
Obstructive sleep apnea — in OSA with obesity, SURMOUNT-OSA had tirzepatide taking roughly 50% off the apnea-hypopnea index. No other GLP-1 carries dedicated OSA trial evidence.
Adolescent (12-17) — Wegovy is the FDA-approved option, supported by STEP-TEENS (Weghuber et al, NEJM 2022). Tirzepatide and orforglipron are not currently approved in this age range.
Stop conditions — a personal or family history of MEN-2 or MTC; breastfeeding; pregnancy, or actively planning one. Treatment in these populations is contraindicated on every FDA GLP-1 label.

References

1.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information, Section 1: Indication and Usage. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Section 1: Indication and Usage. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
3.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — US Prescribing Information, Section 1: Indication and Usage (type 2 diabetes). FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
4.Novo Nordisk Inc. OZEMPIC (semaglutide) injection — US Prescribing Information, Section 1: Indication and Usage (type 2 diabetes). FDA Approved Labeling — DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
5.Novo Nordisk Inc. RYBELSUS (semaglutide) tablets — US Prescribing Information, Section 1: Indication and Usage (type 2 diabetes). FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
6.Novo Nordisk Inc. SAXENDA (liraglutide) injection — US Prescribing Information, Section 1: Indication and Usage. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
7.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information, Section 1: Indication and Usage. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
8.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. PMID: 37952131.
9.Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
10.Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.

GLP-1 BMI Calculator — work out your BMI before you start.
Tirzepatide vs semaglutide head-to-head — the two leading weight-loss options set against each other.
Foundayo vs Wegovy vs Zepbound — all three compared, the new oral GLP-1 included.
SELECT trial cardiovascular benefits.
SURMOUNT-OSA: tirzepatide for sleep apnea.
GLP-1 Glossary — every term the recommendation uses, defined.
Compare every provider — with the drug settled, go find the right seller.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.5